216株鲍曼不动杆菌的临床分布与耐药性分析

目的了解本院鲍曼不动杆菌的临床分布和耐药现状。方法应用VITEK-2鉴定系统对216株鲍曼不动杆菌进行微生物鉴定和药敏分析,采用WHONET 5.6软件对药敏结果进行分析。结果2013年1月至2013年12月共分离鲍曼不动杆菌216株,均来自住院患者,其中痰标本的分离率高达83.3%（180/216）,主要抗菌药物的药敏情况为米诺环素敏感率为90.9%,对头孢哌酮/舒巴坦、美罗培南、左氧氟沙星和复方新诺明的敏感率分别为57.1%、44.44%、59.6%和55.2%。对哌拉西林/他唑巴坦、亚胺培南、头孢吡肟、哌拉西林、庆大霉素、氨苄西林/舒巴坦、头孢他啶和环丙沙星的敏感率均低于30.0%。结论鲍曼不动杆菌的感染主要以呼吸内科与ICU最为常见,其中对米诺环素的敏感率最高。

Distribution and resisitance of clinical isolates of Acinetobacter baumannii

Objective To investigate the distribution and resisitance of clinical isolates of Acinetobacter baumannii. Methods The bacterial susceptibilities to majority of antimicrobial agents were determined by VITEK-2 compact. The results were analyzed by WHONET 5.6 software. Results Total of 216 strains were isolated during the period of January 2013 to December 2013, All of them isolated from inpatient. The isolation rate of Acinetobacter baumannii was 83.7% in sputum specimens. There were 90.9% of them were susceptible to minocycline and the susceptible rate to cefoperazone-sulbacam, meroperem, levofloxacin, trimethoprim-sulfamethoxazole were 57.1%, 44.44%, 59.6%, 55.2%. Less than 30.0% of them were susceptible to piperacillin-tazobactam, imipenem, cefepime, piperacillin, gentamicin, ampicillin/sulbactam, ceftazidime and ciprofloxacin. Conclusions The infection of Acinetobacter baumannii was most serious in ICU, among the antimicrobial agents, sensitive rate of minocycline was highest.